GPT-Rosalind
PulseAugur coverage of GPT-Rosalind — every cluster mentioning GPT-Rosalind across labs, papers, and developer communities, ranked by signal.
- 2026-06-07 product_launch OpenAI expanded its GPT-Rosalind model with life-sciences plugins and controlled access for research. source
- 2026-06-05 product_launch OpenAI expanded GPT-Rosalind with new life sciences reasoning capabilities. source
- 2026-06-03 product_launch OpenAI announced a major upgrade to its GPT-Rosalind model, enhancing its capabilities for drug discovery. source
- 2026-06-03 product_launch OpenAI has launched GPT-Rosalind, a new model series tailored for enterprise-scale life sciences research. source
- 2026-06-03 product_launch OpenAI has launched GPT-Rosalind, an AI model designed to advance life sciences research. source
- 2026-05-29 product_launch OpenAI launched the Rosalind Biodefense program, offering its GPT-Rosalind AI model for pandemic preparedness. source
5 day(s) with sentiment data
-
OpenAI expands GPT-Rosalind for genomics and drug discovery
OpenAI is making its GPT-Rosalind model, designed for genomics and drug discovery, more accessible through controlled research programs. The model has been enhanced with new life-sciences plugins to further its capabili…
-
OpenAI GPT-Rosalind adds life sciences reasoning
OpenAI has integrated new capabilities into its GPT-Rosalind model, specifically enhancing its ability to process and reason about life sciences data. This expansion includes specialized functions for biological reasoni…
-
OpenAI faces lawsuit, expands AWS access, and pushes Codex tool
OpenAI's Codex is being positioned as a production coding tool, but integration challenges like latency and cost remain, making it an early-stage product despite compelling demos. The company also announced GPT-Rosalind…
-
OpenAI upgrades GPT-Rosalind for drug discovery
OpenAI has significantly enhanced GPT-Rosalind, a specialized AI model for drug discovery. The upgrade improves its capabilities in analyzing, designing, and managing experimental workflows within the pharmaceutical res…
-
OpenAI launches GPT-Rosalind for enterprise life sciences research
OpenAI has introduced GPT-Rosalind, a new model series specifically designed for large-scale life sciences research within enterprises. This specialized model aims to provide advanced capabilities tailored to the unique…
-
OpenAI launches GPT-Rosalind for life sciences research
OpenAI has released GPT-Rosalind, an advanced AI model designed to accelerate life sciences research. This new model offers enhanced capabilities in biological reasoning, medicinal chemistry, genomics analysis, and expe…
-
Edgecom Energy launches AI Studio; OpenAI opens GPT-Rosalind
Edgecom Energy has introduced the Agentic AI Energy Studio, a new platform designed to automate operations for energy sector teams. Concurrently, OpenAI has made its GPT-Rosalind model available to government and develo…
-
OpenAI launches AI safety framework and biodefense model
OpenAI has launched the Frontier Governance Framework to manage AI risks and introduced new compliance tools for enterprises. Concurrently, they are initiating the Rosalind Biodefense program, releasing a GPT-Rosalind m…
-
OpenAI offers GPT-Rosalind AI model for pandemic preparedness
OpenAI has launched the Rosalind Biodefense program, offering its life sciences AI model, GPT-Rosalind, to governments globally. This initiative aims to bolster pandemic preparedness and biodefense capabilities. Early c…
-
OpenAI launches Rosalind Biodefense for biodefense and public health
OpenAI has launched Rosalind Biodefense, a program that grants trusted developers and U.S. government partners access to GPT-Rosalind. This initiative aims to bolster biodefense, public health, and pandemic preparedness…
-
AI companies restrict access to powerful models citing safety concerns
Leading AI companies are increasingly withholding their most advanced models, citing dual-use risks in fields like cybersecurity and biosecurity. This trend raises questions about governance and access to powerful AI sy…